Analyst Consensus ?
ConsensusHold18 ratings
Bullish844.4%
Neutral1055.6%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Mettler-Toledo International Inc. · MTD · FY2026 Q1 · Calendar Q2 2026
Mettler-Toledo Q1 EPS Beats, Raises Outlook, but Stock Tumbles 15%
Mettler-Toledo posted a solid Q1 2026 beat with adjusted EPS of $8.91 versus the $8.71 consensus and raised its full-year EPS growth outlook to 8-10%. Yet the stock dropped 15.6% on the report at 4x normal volume, suggesting investors expected more from a premium-priced name. The sales growth target was left unchanged at ~4% in local currency, tariff and inflation headwinds persist, and softness in academic pipette demand and European chemical end-markets remains a concern. The guidance raise was driven by EPS leverage, not a higher top-line outlook, which likely disappointed growth expectations.
Reported After market closeNYSEHealthcare
$28.05B market cap
100quality score
Company context
Snapshot as of publicationMettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domestic U.S. market, Swiss operations, Western European activities, Chinese operations, and an 'Other' segment covering remaining territories. Their extensive product portfolio serves diverse scientific and industrial needs. Within the laboratory sphere, Mettler-Toledo supplies a comprehensive array of equipment, including high-precision balances, advanced liquid handling systems (such as pipetting solutions), automated laboratory reactors, titrators, pH meters, sensors and analyzers for process analytics, instruments for evaluating physical properties, thermal analysis systems, and various other analytical tools. These hardware offerings are complemented by LabX, their proprietary software platform designed for managing and analyzing instrument-generated data.…
Earnings scorecard
Reported versus consensus
Reported EPS
$8.91
Consensus $9
EPS surprise
+2.3%
Reported versus consensus
Reported revenue
$947.1M
Consensus $943.1M
Revenue surprise
+0.4%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$1,382.35Current
$1,100Low
$1,380.85Average
$1,600High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Stifel | Buy | Buy | Maintain | May 18, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 12, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 11, 2026 |
| Baird | Neutral | Neutral | Maintain | May 11, 2026 |
| Citigroup | Buy | Buy | Maintain | May 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 14, 2026 |
| Jefferies | Buy | Hold | Upgrade | Mar 20, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Dec 15, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Sep 22, 2025 |
| UBS | Buy | Neutral | Upgrade | May 20, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 9, 2024 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jan 3, 2019 |
| Deutsche Bank | Hold | Hold | Maintain | May 4, 2018 |
| Cantor Fitzgerald | Buy | Buy | Maintain | Jul 28, 2014 |
| Credit Agricole | Outperform | Underperform | Upgrade | Feb 7, 2013 |
| CL King | Neutral | Buy | Downgrade | Dec 19, 2012 |
| ISI Group | Underweight | Upgrade | Jul 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $1,382.35. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $1,350 | $1,292.74 | -2.3% | Jul 6, 2026 |
| Stifel Nicolaus | Daniel Arias | $1,400 | $1,031.64 | +1.3% | May 18, 2026 |
| Robert W. Baird | Analyst unavailable | $1,194 | $1,124.46 | -13.6% | May 11, 2026 |
| Barclays | Analyst unavailable | $1,500 | $1,345.89 | +8.5% | Apr 14, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $1,475 | $1,382.72 | +6.7% | Feb 9, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $1,445 | $1,373.57 | +4.5% | Feb 9, 2026 |
| Wells Fargo | Analyst unavailable | $1,450 | $1,393.64 | +4.9% | Dec 15, 2025 |
| Susquehanna | Analyst unavailable | $1,600 | $1,393.64 | +15.7% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $1,550 | $1,393.64 | +12.1% | Dec 15, 2025 |
| Goldman Sachs | Analyst unavailable | $1,475 | $1,381.37 | +6.7% | Dec 9, 2025 |
| Morgan Stanley | Kallum Titchmarsh | $1,550 | $1,468.09 | +12.1% | Dec 1, 2025 |
| Evercore ISI | Analyst unavailable | $1,400 | $1,345.27 | +1.3% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $1,350 | $1,289.82 | -2.3% | Oct 2, 2025 |
| Barclays | Analyst unavailable | $1,325 | $1,185.18 | -4.1% | Jun 24, 2025 |
| UBS | Dan Leonard | $1,350 | $1,159.1 | -2.3% | May 19, 2025 |
| Jefferies | Tycho Peterson | $1,100 | $1,100.01 | -20.4% | May 4, 2025 |
| Robert W. Baird | Analyst unavailable | $1,034 | $1,003.16 | -25.2% | Apr 22, 2025 |
| Stifel Nicolaus | Daniel Arias | $1,450 | $1,378.34 | +4.9% | Nov 11, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,550 | $1,441.43 | +12.1% | Aug 5, 2024 |
| Robert W. Baird | Catherine Schulte | $1,375 | $1,441.43 | -0.5% | Aug 5, 2024 |
| Jefferies | Tycho Peterson | $1,250 | $1,404.09 | -9.6% | Jun 3, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,510 | $1,510.25 | +9.2% | May 13, 2024 |
| Robert W. Baird | Catherine Schulte | $1,360 | $1,449.38 | -1.6% | May 13, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,500 | $1,195.02 | +8.5% | Sep 6, 2022 |
| UBS | Elizabeth Garcia | $1,237 | $1,349.73 | -10.5% | Jul 31, 2022 |
| Wells Fargo | Analyst unavailable | $1,410 | $1,284.63 | +2.0% | Apr 25, 2022 |
Track every rating change on MTD the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
-14.8%
Event window
SPY move
+0.8%
Same window
Abnormal move
-15.6%
Stock minus SPY
Volume
4.1×
Versus trailing sessions
Subsequent drift
+1.3%
Up to 20 sessions
MTDSPY benchmark
Follow MTD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q1 2026 sales of $947.1 million edged past the $943.1 million consensus while adjusted EPS of $8.91 beat the $8.71 estimate by 2.3%. Management raised the full-year adjusted EPS growth outlook to 8-10% but kept the ~4% local-currency sales growth target unchanged. Industrial product inspection and food retail drove the strongest organic growth, bioprocessing demand remained solid, and service revenue rose 7%. Novel items include a $6 million Chinese government grant, first-to-market PFAS-free pipette tips, and the expectation of potential tariff refunds excluded from guidance. The stock fell 15.6% with volume at 4x baseline.
Guidance delta
Guidance sentiment shifted from maintained (Q4 2025) to raised (Q1 2026). Management lifted full-year adjusted EPS growth to 8-10% while maintaining the ~4% local-currency sales growth target. The prior full-year adjusted EPS range was $46.05-$46.70 with 60-70 bps of operating margin expansion. The raise reflects EPS performance rather than a higher revenue outlook.
Key takeaways
- Q1 sales grew 3% in local currency; adjusted EPS of $8.91 beat the $8.71 consensus by 2.3%.
- Full-year adjusted EPS growth guidance raised to 8-10%; LC sales growth target held at ~4%.
- Industrial product inspection and food retail delivered the strongest organic growth.
- Service revenue up 7% with continued push to increase attach rates across the installed base.
- Stock fell 15.6% on the report at 4x normal volume despite the beat and raise.
Management priorities
- Ramp up sales of EasyMax reactor and InMotion PX One autosampler
- Expand M50 R-Series and dual-energy X-ray product lines
- Scale PFAS-free pipette tip production
- Leverage R&D Accelerator and JetStream programs for new innovations
- Increase service coverage and attach rates on the installed base
Related earnings events
HealthcareHCA · FY2026 Q2 · Calendar Q3 2026HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex UnveiledDGX · FY2026 Q2 · Calendar Q3 2026Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year GuidanceEW · FY2026 Q2 · Calendar Q3 2026Edwards Lifesciences Beats on Q2, Raises Full-Year Sales Guidance
Sources
- Earnings call transcript and parsed analysis · 2026-06-01T17:24:02.887767+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T17:11:04.772795+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T17:11:04.769888+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.